Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : BRS1RPBDR005
Share Class Description:
BSP:S1RP34: BRDRCompare
Compare
Traded in other countries / regions
SRPT.USAAB3A.GermanyS1RP34.Brazil0L35.UK IPO Date
2020-10-13Description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.26 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1.79 | |||||
| Debt-to-EBITDA | -2.31 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.43 | |||||
| Beneish M-Score | -1.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.2 | |||||
| 3-Year EBITDA Growth Rate | 8.8 | |||||
| 3-Year EPS without NRI Growth Rate | 4.2 | |||||
| 3-Year FCF Growth Rate | 16.6 | |||||
| 3-Year Book Growth Rate | -26.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 47.45 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.18 | |||||
| 9-Day RSI | 91.27 | |||||
| 14-Day RSI | 81.06 | |||||
| 6-1 Month Momentum % | -6.42 | |||||
| 12-1 Month Momentum % | 1.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.44 | |||||
| Quick Ratio | 4.9 | |||||
| Cash Ratio | 3.85 | |||||
| Days Inventory | 585.6 | |||||
| Days Sales Outstanding | 78.99 | |||||
| Days Payable | 276.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.4 | |||||
| Shareholder Yield % | -1.39 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.61 | |||||
| Operating Margin % | -36.14 | |||||
| Net Margin % | -62.52 | |||||
| FCF Margin % | -55.69 | |||||
| ROE % | -113.84 | |||||
| ROA % | -22.17 | |||||
| ROIC % | -46.89 | |||||
| ROC (Joel Greenblatt) % | -187.46 | |||||
| ROCE % | -24.8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 11.34 | |||||
| PS Ratio | 6.7 | |||||
| PB Ratio | 10.25 | |||||
| Price-to-Tangible-Book | 10.51 | |||||
| EV-to-EBIT | -7.85 | |||||
| EV-to-Forward-EBIT | 7.3 | |||||
| EV-to-EBITDA | -8.42 | |||||
| EV-to-Forward-EBITDA | 7.02 | |||||
| EV-to-Revenue | 4.53 | |||||
| EV-to-Forward-Revenue | 2.8 | |||||
| EV-to-FCF | -12.18 | |||||
| Price-to-Median-PS-Value | 0.22 | |||||
| Price-to-Net-Current-Asset-Value | 74.38 | |||||
| Earnings Yield (Greenblatt) % | -12.74 | |||||
| FCF Yield % | -11.5 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 5,582.649 | ||
| EPS (TTM) (R$) | -2.031 | ||
| Beta | -0.34 | ||
| Volatility % | 35.06 | ||
| 14-Day RSI | 81.06 | ||
| 14-Day ATR (R$) | 0.010867 | ||
| 20-Day SMA (R$) | 29.75 | ||
| 12-1 Month Momentum % | 1.29 | ||
| 52-Week Range (R$) | 24.62 - 39.15 | ||
| Shares Outstanding (Mil) | 1,870.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(BSP:S1RP34)'s stock price today?
The current price of BSP:S1RP34 is R$29.75. The 52 week high of BSP:S1RP34 is R$39.15 and 52 week low is R$24.62.
When is next earnings date of Sarepta Therapeutics Inc(BSP:S1RP34)?
The next earnings date of Sarepta Therapeutics Inc(BSP:S1RP34) is 2024-02-28 Est..
Does Sarepta Therapeutics Inc(BSP:S1RP34) pay dividends? If so, how much?
Sarepta Therapeutics Inc(BSP:S1RP34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers